Related Experiment Video
Updated: Apr 25, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
26.0K
Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis
Yu-Lan Yan1, Feng Han, Wen-Min Tan
1Department of Clinical Laboratory, Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China
Asian Pacific Journal of Cancer Prevention : APJCP
|August 30, 2014
Summary
The MDM2 T309G polymorphism is linked to increased leukemia risk, particularly in Asian populations. This meta-analysis clarifies conflicting previous findings on this genetic association.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Conflicting results exist regarding MDM2 (mouse double minute 2 homolog) polymorphisms and leukemia risk.
- Understanding the MDM2 T309G polymorphism's specific role in leukemia development is crucial.
Purpose of the Study:
- To conduct a meta-analysis clarifying the association between MDM2 T309G polymorphism and leukemia risk.
- To evaluate the influence of ethnicity on this genetic association with leukemia.
Main Methods:
- Systematic literature search of PubMed, Web of Science, EMBASE, and CBM databases.
- Meta-analysis of 12 case-control studies (2,362 cases, 5,562 controls) using odds ratios (ORs) and 95% confidence intervals (95% CIs).
Main Results:
- Significant associations between MDM2 T309G polymorphism and increased leukemia risk were found in overall populations across four genetic models.
- Subgroup analysis revealed elevated leukemia risk associated with the MDM2 T309G polymorphism in Asian populations, but not in Caucasians.
Conclusions:
- The MDM2 T309G polymorphism is a risk factor for developing leukemia.
- The association between MDM2 T309G polymorphism and leukemia risk is more pronounced in Asian individuals.
Related Concept Videos
02:23Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
01:20Mismatch Repair
5.4K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.4K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156